10.01.2019 • NewsDede WillamsRegeneronSanofi

Sanofi Pays to Exit Regeneron Pact

Sanofi Pays to Exit Regeneron Pact
Sanofi Pays to Exit Regeneron Pact

France’s Sanofi is paying $462 million to exit the immuno-oncology pact it established with US biotech Regeneron in 2015 half a year earlier than planned.

With the severance agreement, which restructures the original deal originally scheduled to end in mid-2019, the French drugmaker will cover its share of drug discovery costs from the last quarter of 2018 as well as a termination fee and provide development support for two clinical-stage assets. 

As part of the 2015 arrangement four years ago, the Paris-based player paid Regeneron $640 million up front and committed to spending $750 million to take programs up to clinical proof of concept.

In addition increased flexibility to advance its early-stage immuno-oncology pipeline, the new arrangement gives Sanofi the right to opt in to two bispecific programs for two clinical assets as well as increased flexibility to advance its early-stage immuno-oncology pipeline.

Regeneron will retain all rights to its other immuno-oncology discovery and development programs. At the same time, it will commit up to $120 million to fund new developments in the field.

The US biotech will spend up to $70 million to develop the BCMAxCD3 drug in multiple myeloma and as much as $50 million on the MUC16xCD3 bispecific in mucin-16 expressing cancers.  If Sanofi exercises its option on the multiple myeloma asset, it will lead development and fully cover the costs. Regeneron will refund up to 50% of the costs out of its equal split of any profits.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.